Zydus Cadila, a research-driven, global healthcare provider and Medicines for Malaria Venture (MMV) announced a collaboration to develop the investigational antimalarial compound, MMV674253. Zydus will lead the development of the novel compound and MMV will provide support including scientific expertise and access to tools in the field of malaria drug development and delivery.